KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Non-Current Assets (2016 - 2025)

Rigel Pharmaceuticals has reported Other Non-Current Assets over the past 16 years, most recently at $1.9 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 24.95% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, up 24.95%, while the annual FY2025 figure was $1.9 million, 24.95% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $1.9 million at Rigel Pharmaceuticals, up from $1.2 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $5.0 million in Q3 2023 and troughed at $403000.0 in Q2 2022.
  • A 5-year average of $1.9 million and a median of $1.1 million in 2021 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 923.97% in 2023 and later tumbled 75.49% in 2025.
  • Year by year, Other Non-Current Assets stood at $974000.0 in 2021, then crashed by 34.29% to $640000.0 in 2022, then skyrocketed by 377.34% to $3.1 million in 2023, then plummeted by 50.02% to $1.5 million in 2024, then increased by 24.95% to $1.9 million in 2025.
  • Business Quant data shows Other Non-Current Assets for RIGL at $1.9 million in Q4 2025, $1.2 million in Q3 2025, and $4.2 million in Q2 2025.